A Clinical Trial of Telehealth Treatment for Opioid Use Disorders
A Randomized Clinical Trial of Telehealth Treatment for Opioid Use Disorders
3 other identifiers
interventional
470
1 country
1
Brief Summary
This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 21, 2026
CompletedFirst Posted
Study publicly available on registry
January 23, 2026
CompletedStudy Start
First participant enrolled
April 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
March 24, 2026
March 1, 2026
1.5 years
January 21, 2026
March 20, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Mean time to first buprenorphine prescription
Mean time to first buprenorphine prescription within 30 days of engagement with RP.
30 days post enrollment
Secondary Outcomes (3)
Number of participants with current MOUD prescription
90 days post enrollment
Mean number overdose events
30 and 90 days post enrollment
Number of participants with methadone referral and induction
90 days post enrollment
Study Arms (2)
RecoveryPad platform
EXPERIMENTALParticipants randomized to RecoveryPad platform
Treatment as usual
NO INTERVENTIONTreatment as usual: referrals to harm reduction and other community resources that are already being given to individuals in the various community and healthcare settings from which these participants are being recruited.
Interventions
Telehealth platform to enhance motivation and engagement in treatment for OUD
Eligibility Criteria
You may qualify if:
- Can speak, read and write in English
- Provision of signed and dated informed consent form
- Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
- Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)
- Can provide a working email address OR be willing to create one
You may not qualify if:
- Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
- Pregnancy or lactation
- Known current suicide risk based on participant self-report
- On parole or incarcerated at time of enrollment based on participant self-report
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
Yale University
New Haven, Connecticut, 06520, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rebekah Heckmann, MD
Yale University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 21, 2026
First Posted
January 23, 2026
Study Start
April 15, 2026
Primary Completion (Estimated)
October 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
March 24, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share